TB-500 Dosage: What the Research Actually Recorded
Scientists studying TB-500 dosage parameters have recorded a wide range of experimental doses across animal and early-phase human models. This guide explains what those figures mean, where they came from, and how to read them accurately.
What Is TB-500, in Plain English?
In the 1960s, scientists at the National Cancer Institute noticed something unusual. Extracts from the thymus gland, a small organ in the chest, seemed to help the immune system repair damage faster than expected. Decades of investigation eventually led researchers to a short chain of amino acids (the small building blocks that cells use to make proteins) they named thymosin beta-4 (TB4). TB-500 is a synthetic, lab-made fragment of that natural molecule, built to isolate what researchers believed was its most biologically active segment: the LKKTET amino acid sequence.
Think of the full thymosin beta-4 protein as a long sentence. TB-500 is just one key phrase. Scientists wanted to know whether that phrase alone could do much of what the whole sentence does.
Scientists find thymosin beta-4 interesting because of how it interacts with actin. Actin is a protein that acts like the internal scaffolding of a cell. When a cell needs to move, actin rearranges itself. Thymosin beta-4 binds to actin and appears to help regulate that rearrangement, which is one reason it has been linked to cell migration and wound repair in laboratory models. TB-500 is thought to share this activity, though direct evidence for the fragment specifically is more limited than for the full protein.
Regulatory and Approval Status
TB-500 has no FDA approval for any human or veterinary application. It is classified as a research compound available for laboratory investigation only. The regulatory note at the top of this page contains a linked FDA reference for verification. In professional sports, WADA (the World Anti-Doping Agency) prohibits thymosin beta-4 and its fragments, including TB-500, under the S2 peptide hormones category.
What TB-500 Dosage Parameters Looked Like in Animal Studies
Most of what researchers know about TB-500 dosage comes from experiments run on rats and mice, not humans. The figures below are what specific studies recorded in their methods sections for specific animal models.
How Researchers Designed Early Wound Experiments
In a 1999 rat full-thickness wound model, researchers administered thymosin beta-4 both topically (applied directly to the skin) and intraperitoneally (injected into the abdominal cavity of the rat). The study, published in the Journal of Investigative Dermatology, reported that the peptide was administered at doses starting from as little as 10 picograms per assay in in-vitro cell migration assays, and in concentrations the researchers applied systemically in the rat model. At day four, wounds in the treated rat group had re-epithelialized (grown new surface skin) 42% faster than saline-control rats. At day seven, that figure reached 61%. (Malinda et al., J Invest Dermatol. 1999. PMID: 10469335)
It is essential to understand what this means for reading TB-500 dosage numbers: the doses in this study belong to that rat model, in that laboratory, under those specific conditions. They are experimental parameters, not reference ranges that apply to other situations.
Ligament and Tendon Models
A 2013 study published in Experimental Physiology examined thymosin beta-4 in a rat medial collateral ligament injury model. Researchers found that Tb4 elevated granulation tissue deposition, induced angiogenesis (the growth of new blood vessels), and enhanced collagen deposition at the wound site. Collagen is the fibrous protein that forms connective tissue. The study used a defined dose administered to the rat subjects over a specific recovery window. Importantly, the researchers noted that these results in rodent ligament models do not automatically predict what would happen in a different tissue type or in a larger animal. (Treadwell et al., Exp Physiol. 2013)
Anti-Doping Pharmacokinetic Work
The most specific TB-500 dosage data published comes not from therapeutic research but from anti-doping science. A 2012 study by Ho et al. developed a detection method for TB-500 (identified as Ac-LKKTETQ, the acetylated fragment) in equine (horse) plasma and urine. The study administered TB-500 to horses to map its metabolites and detection window. This work confirmed how TB-500 is chemically processed by a large mammal’s body, but it was designed to catch doping, not to evaluate any therapeutic effect. A 2024 follow-up study by Rahaman et al. confirmed and extended this pharmacokinetic mapping in horses. (Ho et al., Drug Test Anal. 2012. PMID: 23084823; Rahaman et al., Drug Test Anal. 2024. PMID: 38382158)
Loading Phase and Maintenance Dose as Research Concepts
The terms “loading phase” and “maintenance dose” appear often in discussions of TB-500 dosage, but they originate in how researchers structure multi-week animal experiments, not in any approved clinical protocol.
What Loading Phase Means in Research Design
In multi-week studies on thymosin beta-4, some researchers have used an initial period of higher-frequency administration followed by a reduced frequency in later weeks. This design was intended to saturate tissue and observe whether early high exposure changed the repair timeline versus a steady-state approach. The concept mirrors pharmacological study design in many drug classes: give subjects a higher initial dose to reach a target exposure quickly, then reduce to maintain it. In the published thymosin beta-4 literature, this structure appears in preclinical models reviewed by Smart et al. (2010) in Annals of the New York Academy of Sciences. The review examined topical and systemic uses across multiple animal models, noting that administration frequency was tailored to each model’s expected healing timeline. (Smart et al., Ann N Y Acad Sci. 2010. PMID: 20536453)
Maintenance Dose: What the Research Framing Means
A maintenance dose in research describes the amount a study continued administering after an initial phase to sustain the biological signal being measured. In thymosin beta-4 cardiac repair studies, for example, researchers gave rat subjects the compound at specific intervals after an induced myocardial infarction (a heart attack caused in the lab) to track whether the tissue response was sustained. The dose figures in those studies are properties of those experimental designs, specific to the rat cardiac model, the injury type, and the readout being tracked. (Becker & Bhatt, PMC. 2021. PMC8228050)
Research Insight: Why Dose Figures Don’t Transfer Directly
- Animal studies use weight-based dosing (e.g., micrograms per kilogram of body weight). A dose that produces a measurable effect in a 300-gram rat cannot simply be scaled to a much heavier organism without testing how the compound is distributed, metabolized, and cleared in that organism.
- Route of administration (subcutaneous means “under the skin”; intraperitoneal means “into the abdominal cavity”) affects how quickly and how completely a compound reaches its target.
- The tissue model matters. Doses in skin wound studies differ from doses used in cardiac or corneal models, because different tissues respond differently.
The TB-500 Dosing Schedule in Anti-Doping Context
The most detailed TB-500 dosing schedule data comes from equine anti-doping research. Researchers in that field administered known quantities to horses and sampled blood and urine at intervals to map the detection window. The TB-500 dosing schedule used in those experiments was designed purely to produce detectable metabolite profiles, not to test any tissue effect. Understanding this distinction prevents a common reading error: seeing a number from a detection study and treating it as a therapeutic reference. (Kwok et al., Rapid Commun Mass Spectrom. 2013. PMID: 23318763)
What TB-500 Dosage Research Can’t Tell Us Yet
Knowing the limits of the evidence is what separates good science reading from bad. Here are the key gaps in the current TB-500 dosage literature.
- Because most studies used animal models, we can’t yet say how the doses tested in rats or horses would need to be adjusted for different species, body sizes, or metabolic rates in other organisms.
- Because no published human clinical trial has specifically tested TB-500 dosage in a controlled setting, we can’t yet say what dose of TB-500 specifically (as opposed to full thymosin beta-4) produces any biological effect in humans.
- Because anti-doping studies were designed to detect the compound, not to measure tissue effects, we can’t yet say whether the doses administered in those equine experiments had any measurable biological impact on the horses beyond being detectable.
- Because TB-500 cycle length in research varied by model and objective, we can’t yet say whether any particular duration of administration is superior to any other, or what long-term administration looks like physiologically.
- Because TB-500 is a fragment rather than the full thymosin beta-4 molecule, we can’t yet say with confidence that all Tb4 findings apply equally to the synthetic fragment, since the surrounding peptide sequence may play a role in activity.
Issue: All wound-healing dose data comes from rodents. Research Gap: There is no dose-response curve established for TB-500 in humans for any indication.
Issue: TB-500 cycle length in existing studies ranged from days to weeks depending on model. Research Gap: There is no published data on outcomes beyond the typical preclinical study window in any mammal.
The body of evidence on TB-500 dosage draws from anti-doping pharmacokinetics and a larger set of thymosin beta-4 preclinical studies. Every item below is a cited finding from a named study.
How to Make Sense of TB-500 Dosage Research
Understanding research design is what lets a curious reader get real value from the science rather than reading a number and stopping there.
Factor 1: What Kind of Study Was It?
Three types of studies appear in the TB-500 dosage literature: in-vitro (in lab dishes, not in a living body), in-vivo animal (in a living rat, mouse, or horse), and the rare human pilot. Each type tells you something different. Lab-dish results show that a molecule can interact with cells. Animal results show that it does something in a living body. Human results show whether any of that translates. TB-500 has in-vitro and animal evidence, plus human data from thymosin beta-4 clinical trials, but not from TB-500 specifically.
When you read a TB-500 dosage figure, ask: what kind of study was this? If it was in a rat, the number tells you what the researchers gave the rat. Period.
Factor 2: Weight-Based Dosing vs. Fixed Dosing
Animal studies typically express doses as micrograms per kilogram of body weight (mcg/kg). This means the same dose number means very different absolute amounts depending on the animal’s size. A dose of 100 mcg/kg in a 300-gram rat is 30 micrograms total. Applying that same ratio to a much larger organism is not straightforward, because body surface area, metabolic rate, and clearance mechanisms scale differently with size. This is why even translating from rat data to a larger mammal requires careful allometric scaling in pharmacology.
Factor 3: Route of Administration
The route used in a study, whether topical, subcutaneous (injected just under the skin), intraperitoneal (injected into the abdomen), or intravenous, changes how much of the compound reaches its target, how fast, and for how long. A topical dose in a wound healing study does not behave the same way as a subcutaneous injection in a pharmacokinetics study. When reading TB-500 dosage data, the route is inseparable from the dose figure.
Anti-doping equine studies used specific administration routes to model what a doping scenario would look like. Those routes were chosen for experimental validity, not for any other reason.
Want to explore the published science directly? Browse the Phoenix Peptide Labs research library →
Factor 4: Sample Size and Study Power
A randomized controlled trial involves researchers sorting people at random into a group that gets the compound and a group that gets a placebo, which is the study setup scientists trust most for establishing cause and effect. Most TB-500 dosage research has been done in small groups of animals, not in large randomized trials. The thymosin beta-4 wound-healing trials that reached humans typically enrolled fewer than 100 participants, which is too small to draw broad conclusions from.
Factor 5: Who Funded the Study?
Funding source does not automatically invalidate research, but it is part of reading a study critically. Much of the thymosin beta-4 literature was supported by RegeneRx Biopharmaceuticals, the company that held patents on the compound. Industry-funded studies are not inherently flawed, but they benefit from independent replication, which has been limited for TB-500 specifically.
Factor 6: Has It Been Replicated?
Science gains confidence through replication: when independent researchers in different labs find similar results, the finding is more reliable. The wound-healing findings for thymosin beta-4 have been replicated across multiple animal models, which strengthens that evidence base. TB-500-specific replication is much thinner, because TB-500 has been studied primarily in anti-doping contexts rather than in therapeutic research.
What Does Replication Mean for Reading Dosage Data?
It means that a dose figure from one lab, in one species, in one model should be treated as a single data point, not a consensus. If three independent labs using different methods found the same dose range to produce similar effects, that would carry more evidential weight.
TB-500 Research Parameter Reference
The table below summarizes the study parameters reported in key published research. Every figure is attributed to its source model and citation. These are experimental records, not general reference ranges.
| Study / Source | Compound Studied | Model | Route | Key Finding | Limitation |
|---|---|---|---|---|---|
| Malinda et al., 1999 (PMID: 10469335) | Thymosin beta-4 | Rat full-thickness wound | Topical + intraperitoneal | 42-61% faster re-epithelialization vs. controls | Rodent model; no human translation established |
| Treadwell et al., 2013 (Exp Physiol) | Thymosin beta-4 | Rat medial collateral ligament injury | Systemic injection | Elevated granulation tissue, collagen, angiogenesis | Single rodent model; ligament-specific only |
| Sosne et al., 2002 (PMID: 12070524) | Thymosin beta-4 | Corneal injury model | Topical ocular | Reduced inflammation; improved corneal cell migration | Isolated tissue model; not systemic |
| Ho et al., 2012 (PMID: 23084823) | TB-500 (Ac-LKKTETQ) | Horse (equine) | Parenteral (injection) | TB-500 and metabolites detected in plasma/urine | Detection study only; no therapeutic effect measured |
| Rahaman et al., 2024 (PMID: 38382158) | TB-500 | Horse (equine) | Parenteral (injection) | Extended metabolite profile and detection window confirmed | Anti-doping focus only; no tissue outcome measured |
| Becker & Bhatt, 2021 (PMC: 8228050) | Thymosin beta-4 | Rat cardiac infarction model | Subcutaneous | Supported new vessel formation, reduced scar tissue in rat hearts | Rodent cardiac model only; no confirmed human equivalent |
| Xing et al., 2021 (PMC: 8724243) | Thymosin beta-4 (review) | Multiple models reviewed | Various | Consistent repair-related effects across skin, eye, cardiac, musculoskeletal models | Review article; human clinical confirmation pending for most indications |
Where TB-500 Dosage Research Shows Up
Three distinct research territories have produced the TB-500 dosage and protocol data that exists today. Each has a different purpose, different methods, and different open questions.
Equine Pharmacokinetics
The Finding: When TB-500 was administered to horses at known doses, researchers were able to detect the compound and its breakdown products in blood and urine for a measurable window. This represents the most granular TB-500-specific dosage data in the published literature.
The Open Question: Does the pharmacokinetic profile observed in a large horse predict anything about how TB-500 would move through other species?
Takeaway: This research tells us a lot about detection but almost nothing about tissue effects at any given dose.
Preclinical Tissue Repair Models
The Finding: Across multiple rodent models of skin, ligament, cornea, and cardiac injury, thymosin beta-4 administered at various doses produced measurable differences in tissue repair markers compared to control groups. Dosing in these studies varied by tissue type, administration route, and expected healing window.
The Open Question: Do the doses used in rodent models translate meaningfully to larger or more complex organisms? Which tissue types show the strongest or weakest dose-response relationship?
Takeaway: Strong preclinical foundation, but the human translation question remains largely open.
Thymosin Beta-4 Clinical Studies
The Finding: RegeneRx Biopharmaceuticals conducted human pilot trials of full thymosin beta-4 (not TB-500 specifically) in dermal wound, corneal, and cardiac indications. A Phase 2 trial in pressure ulcers enrolled participants and tracked wound closure. Results were mixed, and none reached Phase 3 approval. (ClinicalTrials.gov NCT00832091)
The Open Question: Would a TB-500 fragment trial produce similar, stronger, or weaker results than full Tb4 trials? No published study answers this yet.
Takeaway: Human data exists for the parent molecule, not for the fragment. That distinction matters when evaluating dosage claims.
Frequently Asked Questions About TB-500 Dosage
Here are the questions researchers and curious readers most often bring to the TB-500 literature, answered plainly with citations.
TB-500 is a short, synthetic chain of amino acids modeled after the most biologically active region of thymosin beta-4, a naturally occurring protein found in most cells of the human body. Thymosin beta-4 is involved in binding actin (the scaffolding protein inside cells) and plays a role in cell migration and tissue repair. TB-500 isolates the LKKTET sequence, which researchers believe carries much of this activity. The full thymosin beta-4 molecule is 43 amino acids long. TB-500 is seven. (Goldstein & Kleinman, 2012. PMID: 22074294)
The story starts in the 1960s when researchers at the National Cancer Institute found that thymus-derived proteins affected immune function and tissue repair. Thymosin beta-4 was isolated from calf thymus and studied extensively over the following decades. TB-500 emerged when scientists sought to identify the shortest fragment of thymosin beta-4 that retained biological activity, specifically the actin-binding function linked to cell motility. The LKKTET sequence was identified as that key region, and synthetic versions were produced for research and, eventually, anti-doping testing. (Goldstein & Kleinman, Expert Opin Biol Ther. 2012)
TB-500-specific dosage data comes primarily from anti-doping studies in horses, where researchers administered known quantities to map detection windows. These studies confirmed how the compound is processed biochemically but were not designed to measure tissue effects at any dose. Most dosage information associated with TB-500 in repair-related research is extrapolated from thymosin beta-4 preclinical studies, where doses were administered to rodents (rats or mice) in wound, cardiac, and corneal models at figures that cannot be directly generalized. (Ho et al., 2012. PMID: 23084823; Smart et al., 2010. PMID: 20536453)
Several significant unknowns remain. No peer-reviewed study has established a dose-response curve for TB-500 specifically in any mammal for any therapeutic outcome. The long-term effects of TB-500 administration have not been studied in any species. It is not established whether TB-500 behaves identically to full thymosin beta-4, since the surrounding amino acid sequence may contribute to activity. Whether any of the rodent findings for thymosin beta-4 replicate in humans at any dose is not confirmed. The safety profile of repeated TB-500 administration is not published in any peer-reviewed study. (Xing et al., Front Pharmacol. 2021. PMC8724243)
Safety data for TB-500 specifically is sparse. Anti-doping studies in horses were not safety studies. The closest safety-relevant data comes from thymosin beta-4 human pilot trials, where the compound was generally well-tolerated at the doses studied, with no severe adverse events reported in those small cohorts. However, those trials used full thymosin beta-4, not the TB-500 fragment, and enrolled small numbers of participants. Researchers have noted a theoretical concern about compounds that promote angiogenesis (new blood vessel growth): in contexts where abnormal tissue growth already exists, stimulating additional vessel formation could be counterproductive. This is a research hypothesis, not a confirmed finding for TB-500. (ClinicalTrials.gov NCT00832091)
TB-500 is not approved by the U.S. Food and Drug Administration for any human or veterinary use. It is not an ingredient in any FDA-approved drug. The parent molecule, thymosin beta-4, was studied in clinical trials but never reached approval for any indication. TB-500 exists exclusively as a research compound, restricted to laboratory use by qualified researchers. (FDA Drug Approvals Database)
In the 1999 Malinda et al. rat wound model, thymosin beta-4 was applied topically and intraperitoneally; cell migration assays used concentrations starting at 10 picograms per assay. In the 2010 Smart et al. review of animal studies, doses across models were described as weight-based (mcg/kg) and varied by tissue type and administration route, with each study citing its own protocol. In the equine anti-doping studies by Ho et al. (2012) and Rahaman et al. (2024), known amounts of TB-500 were administered by injection to horses for metabolite mapping purposes. None of these figures represent a validated protocol for any other context. (PMID: 10469335; PMID: 20536453; PMID: 23084823)
A Certificate of Analysis (COA) is a document from an independent laboratory that verifies a compound’s identity, purity, and potency using analytical chemistry methods. HPLC (high-performance liquid chromatography, a technique that separates and measures individual molecules in a mixture) is the standard method for peptide purity verification